Friday, July 8, 2022 Daily Archives

Podcast: Fujifilm Diosynth CEO on pandemics, CAPEX, and CGT ambitions

by

Martin Meeson discusses Fujifilm Diosynth Biotechnologies’s role in pandemics past and future, and why the CDMO just won’t stop investing in capacity. The BioProcess Insider Expression Platform (BIEP) is back, bringing you some of the conversations you may have missed at BIO 2022 in San Diego, California. We sat down with Martin Meeson, CEO of Fujifilm Diosynth Biotechnologies, to discuss industry’s learnings from the pandemic. “[COVID-19] was a pandemic but I just worry we forget and we won’t use the…

July 8, 2022

Avid opens viral vector facility, looks to FY23 to fill GMP capacity

by

Avid Bioservices has completed the first phase of its journey into cell and gene therapies, opening analytical and process development capabilities in California. In October 2021, biologics contract development and manufacturing organization (CDMO) Avid announced plans to move into the cell and gene therapy space through the construction of a 53,000 square-foot viral vector development and GMP manufacturing facility at a cost of between $65 and $75 million. After eight months and with help from engineering and construction firm CRB,…

July 8, 2022

Portage targets adenosine pathway with Tarus acquisition

by

Portage Biotech will gain four assets targeting various aspects of the adenosine pathway through the acquisition of Tarus Therapeutics. The agreement to acquire adenosine receptor development firm Tarus for an upfront payment of $21 million “will allow Portage to expand [its] capabilities of developing first-in-class immuno-oncology treatments for patients with cancer,” Ian Walters, CEO of Portage told BioProcess Insider. Under the terms of the deal, Portage will gain four new assets acquired from Tarus: TT-10 (now PORT-6):an adenosine receptor type…

July 8, 2022